Recent Company News

• 08:47 AM ET May 18, 2026
  

  Sihuan Pharmaceutical Holdings Group buys back 10.0M shares at HK$1.0685/sh on 18-May

• 08:40 PM ET May 12, 2026
  

  Sihuan Pharmaceutical Holdings Group initiated overweight at Northeast Securities (12-May, timing uncertain) (HK$1.15, 0.00)

• 10:30 PM ET Apr 29, 2026
  

  Sihuan Pharmaceutical Holdings Group initiated buy at China Securities Co Ltd (HK$1.29, 0.00)

• 10:59 PM ET Apr 21, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 12:07 AM ET Apr 20, 2026
  

  Sihuan Pharmaceutical Holdings Group presents phase III DIAMOND-2 data for dirozalkib in 1L ALK+ advanced NSCLC at AACR 2026 (HK$1.30, -0.03)

• 06:09 PM ET Apr 14, 2026
  

  Xuanzhu Biopharmaceutical receives CDE approval to initiate phase iii clinical trial for new indication of ANAPRAZOLE sodium (HK$32.60, 0.00)

• 05:06 AM ET Apr 01, 2026
  

  Sihuan Pharma and Biocytogen signs strategic collaboration agreement to conduct innovative drug R&D (HK$1.45, 0.00)

• 12:05 AM ET Mar 31, 2026
  

  Sihuan Pharmaceutical Holdings Group reports FY net income attributable CNY179.7M vs year-ago (CNY216.7M) (HK$1.37, +0.03)

• 07:22 AM ET Mar 24, 2026
  

  Xuanzhu Biopharmaceutical provides final analysis results from phase 3 trial of bireociclib-fulvestrant combination for breast cancer (HK$37.60, 0.00)

• 03:29 PM ET Mar 22, 2026
  

  Xuanzhu Biopharmaceutical reports phase III clinical trial of Anaprazole Sodium Enteric-coated tablets completes enrollment (HK$43.00, 0.00)